SEC Tracker
Get the app

Parabilis Medicines PBLS

Parabilis Medicines Q2 FY26: revenue $148K; diluted EPS −$2.32

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Parabilis Medicines reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$148KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$52.5MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$2.32No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.1BNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Parabilis Medicines files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Dare Bioscience DARE public float $21M, Jun 30, 2025
  2. Lipocine LPCN public float $16M, Jun 30, 2025
  3. Clearside Biomedical CLSD
  4. Cocrystal Pharma COCP public float $12M, Jun 30, 2025
  5. Cardiff Oncology CRDF public float $205M, Jun 30, 2025